Table 3.
Comparative efficacy of glimepiride in patients with type 2 diabetes
| Reference | Study design | Drug regimen (mg) | Results |
|---|---|---|---|
| Goldberg et al29 | DB, R, PC 14-weeks |
G 0, 1, 4 or 8 qd | Median FPG, PPG and HbA1c at all G does significantly lower than P (P < 0.05) |
| Sonnenberg et al30 | DB, R, CO 8-weeks |
G 3 bid or 6 qd | Glycemic control equivalent between qd and bid regimens |
| Rosenstock et al31 | DB, R, PC 14-weeks |
G 0 qd, 4 bid, 8 qd, 8 bid or 16 qd | Median FPG and HbA1c at all G does significantly lower than P (P < 0.001) |
| Draeger et al37 | DB, R 52-weeks |
G 1–8 qd or glyburide 2.5 to 20 qd or bid | Similar (significant) reductions in FPG and HbA1c in both groups |
| Dills et al36 | DB, R 52-weeks |
G 1–16 qd or glyburide 1.25–20 qd | Similar (significant) reduction in FPG and HbA1c in both groups; significantly lower C peptide and fasting insulin concentrations with G than with glyburide |
| Riddle41 | DB, R, PC 24-weeks |
Insulin ± G 8 bid | Significantly reduced exogenous insulin requirement with G compared with P |
| Schernthaner et al38 | DB, R 27-weeks |
G 1–6 mg or Gliclazide modified release (MR) 30–120 mg | Similar reduction in FPG and HbA1c in both groups Safety of glimepiride was better |
| Charpentier et al33 | DB, R 20-weeks |
G 1–6 mg OD M 850 tid |
No difference in HbA1c or FBG with either agent as monotherapy glimepiride more effective in reducing PPBG |
| Jeon and Oh63 | OL, R 32-weeks |
V50 mg bid plus M500 mg bid or V 50 mg bid plus G 2 mg bid | Comparable efficacy of both groups in reducing HbA1c Less risk of hypoglycemia with V group |
Abbreviations: bid, twice daily; DB, double-blind; FPG, fasting plasma glucose; G, glimepiride; HbA1c, glycosylated hemoglobin; M, metformin; OL, open-label; PC, placebo-controlled; PPG, postprandial glucose; R, randomized; tid, three times daily; qd, once daily; V, vildagliptin.